MFC Co

MFC Co Intangible Assets

The Intangible Assets of MFC Co (432980.KQ) as of Nov 3, 2026 is 255.94 M KRW. In the previous year, Intangible Assets was 255.94 M KRW — a change of 0.00% (lower).

Intangible Assets

255.94 MKRW

YoY

0.00%

Last updated:

Intangible Assets of MFC Co is 2024 255.94 M KRW. Intangible Assets of MFC Co was 2023 255.94 M KRW. It decreases by 0.00% lower compared to the previous year.

The MFC Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2022
255.94 M KRW
Jan 1, 2023
255.94 M KRW
Jan 1, 2024
255.94 M KRW
The MFC Co Intangible Assets history
YEARIntangible AssetsYoY
255.94 MKRW0.00%
255.94 MKRW0.00%
255.94 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MFC Co Stock analysis

What does MFC Co do? MFC Co Ltd generates revenue primarily through the development and production of active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials for the pharmaceutical industry. The company focuses on creating basic pharmaceutical substances and raw material pharmaceuticals, serving clients in the pharmaceutical sector. Its products are sold to pharmaceutical manufacturers who require these materials for drug formulation. The company operates within the pharmaceutical research and development segment, targeting firms involved in drug production and formulation. MFC Co Ltd's business model centers on providing essential raw materials and intermediates to pharmaceutical companies. By specializing in API, KSM, and intermediate materials, the company supports the manufacturing processes of its clients. The firm's revenue streams are derived from the sale of these specialized pharmaceutical components to manufacturers who integrate them into their final drug products. The company's target market consists of pharmaceutical manufacturers requiring high-quality raw materials for their production lines. The company's core offerings include active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials, which are critical for pharmaceutical manufacturing. These products are sold to pharmaceutical manufacturers as part of their supply chain. MFC Co Ltd's revenue is generated through the direct sale of these materials to clients in the pharmaceutical industry. The company's focus on R&D for pharmaceutical substances ensures a steady demand for its products from drug manufacturers seeking reliable suppliers. MFC Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MFC Co stock

Intangible Assets of MFC Co is 255.94 M KRW in 2024.

Intangible Assets of MFC Co changed from 255.94 M KRW to 255.94 M KRW, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets MFC Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's MFC Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — MFC Co

All Key Metrics — MFC Co